Taysha Gene Therapies is trading at $4.38 (+5.44%), with the reason for the gain unclear.
- No verified company-specific announcement explaining the October 29 move was found; the investor-relations page lists its latest releases as dated October 1 and October 2.
- Astellas coverage surfaced in search but does not establish a new October 29 catalyst. Shares are rising while the supplied market context describes technology weakness.